JP2018511325A5 - - Google Patents

Download PDF

Info

Publication number
JP2018511325A5
JP2018511325A5 JP2017550936A JP2017550936A JP2018511325A5 JP 2018511325 A5 JP2018511325 A5 JP 2018511325A5 JP 2017550936 A JP2017550936 A JP 2017550936A JP 2017550936 A JP2017550936 A JP 2017550936A JP 2018511325 A5 JP2018511325 A5 JP 2018511325A5
Authority
JP
Japan
Prior art keywords
got1
polypeptide
purifying
preparation
sumo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550936A
Other languages
English (en)
Other versions
JP2018511325A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2016/050346 external-priority patent/WO2016157190A1/en
Publication of JP2018511325A publication Critical patent/JP2018511325A/ja
Publication of JP2018511325A5 publication Critical patent/JP2018511325A5/ja
Pending legal-status Critical Current

Links

Claims (5)

  1. グルタミン酸オキサロ酢酸トランスアミナーゼ1(GOT1)ポリペプチド分子を含むタンパク質調製物であって、前記GOT1ポリペプチド分子の100%が、前記GOT1ポリペプチドの1位にアラニンを有し、前記GOT1ポリペプチドが、配列番号2に示されるアミノ酸配列からなり、前記GOT1ポリペプチド分子は、前記調製物中のタンパク質の100%を構成する、タンパク質調製物。
  2. 活性な作用物質として請求項1に記載のタンパク質調製物、および薬学的に許容され得る担体を含む、薬学的組成物。
  3. 過剰なグルタメートに関連する疾患または状態の処置に使用される、請求項1に記載の調製物または請求項2に記載の薬学的組成物
  4. 前記疾患または状態が脳の疾患または状態であり、前記脳の疾患が中枢神経系の癌、脳虚血および神経変性疾患からなる群より選択される、請求項3に記載の調整物または薬学的組成物
  5. GOT1ポリペプチドを精製する方法であって、前記方法は、
    (a)前記GOT1ポリペプチドおよびSUMOを含む融合タンパク質を宿主細胞において発現させる工程であって、前記GOT1ポリペプチドのN末端は、前記SUMOのC末端に翻訳段階で融合され、前記融合タンパク質は、前記SUMOまたは前記GOT1に天然には含まれないいかなるアミノ酸配列も欠く、工程;
    (b)前記宿主細胞を破壊し、前記融合タンパク質を放出させる工程、
    (c)前記融合タンパク質から前記SUMOを除去する工程;および
    (d)前記宿主細胞から前記GOT1ポリペプチドを単離する工程であって、前記単離する工程は、
    (i)熱処理によって前記GOT1を精製する工程;
    (ii)塩誘導沈殿によって前記GOT1を精製する工程;
    (iii)混合モードクロマトグラフィーによって前記GOT1を精製する工程;
    (iv)陽イオン交換クロマトグラフィーによって前記GOT1を精製する工程;および
    (v)陰イオン交換クロマトグラフィーによって前記GOT1を精製する工程
    によって実施され、ここで、工程(c)および(d)は、工程(a)および(b)の後に行われ、工程(v)は、工程(iv)の後に行われ、工程(iv)は、工程(iii)の後に行われ、工程(ii)は、工程(i)の後に行われるものである、工程と、を含む、方法。
JP2017550936A 2015-03-31 2016-03-31 グルタミン酸オキサロ酢酸トランスアミナーゼ1(got1)、その調製物および製造方法およびその使用 Pending JP2018511325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140492P 2015-03-31 2015-03-31
US62/140,492 2015-03-31
PCT/IL2016/050346 WO2016157190A1 (en) 2015-03-31 2016-03-31 Glutamate oxaloacetate transaminase 1 (got1), preparations and methods of generating same and uses thereof

Publications (2)

Publication Number Publication Date
JP2018511325A JP2018511325A (ja) 2018-04-26
JP2018511325A5 true JP2018511325A5 (ja) 2019-04-11

Family

ID=55795016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017550936A Pending JP2018511325A (ja) 2015-03-31 2016-03-31 グルタミン酸オキサロ酢酸トランスアミナーゼ1(got1)、その調製物および製造方法およびその使用

Country Status (11)

Country Link
US (1) US20180071369A1 (ja)
EP (1) EP3277308A1 (ja)
JP (1) JP2018511325A (ja)
KR (1) KR20170132293A (ja)
CN (1) CN107771217A (ja)
AU (1) AU2016242298A1 (ja)
BR (1) BR112017021016A2 (ja)
CA (1) CA2979309A1 (ja)
HK (1) HK1243329A1 (ja)
RU (1) RU2017135552A (ja)
WO (1) WO2016157190A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
RU2712193C1 (ru) * 2018-07-27 2020-01-24 Общество с ограниченной ответственностью научно-технический центр "БиоКлиникум" (ООО НТЦ "БиоКлиникум") Способ лечения поражения нервной системы с помощью рекомбинантной глутаматоксалоацетаттрансаминазы

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
AU2003205053B2 (en) * 2002-01-07 2008-10-16 Lifesensors, Inc. Methods and compositions for protein expression and purification
AU2003247143B2 (en) * 2002-08-01 2009-07-16 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
GB0315248D0 (en) * 2003-06-30 2003-08-06 Hoffmann La Roche HCV regulated protein expression
WO2006069610A2 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
EP2096177A3 (en) * 2004-12-17 2010-01-13 Metanomics GmbH Process for the production of lutein
US8119369B2 (en) 2004-12-30 2012-02-21 Lifesensors, Inc. Human SUMO-3 for enhancing protein expression
US20100048480A1 (en) * 2006-11-22 2010-02-25 Bettina Bommarius Production of anti-microbial peptides
EP2109673B1 (en) * 2006-12-29 2015-03-11 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
ES2534936T3 (es) * 2010-08-02 2015-04-30 Ratiopharm Gmbh Método para producir y purificar una sialiltransferasa soluble activa
ES2525573T3 (es) * 2011-05-24 2014-12-26 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Trampas de SUMO de alta afinidad

Similar Documents

Publication Publication Date Title
HRP20192314T1 (hr) Pripravci faktora viii i postupci pripreme i njihove uporabe
JP2012522736A5 (ja)
US20180214579A1 (en) Polynucleotide compositions containing amino acids
JP2017529097A5 (ja)
HRP20201031T1 (hr) Anti-ctla-4 protutijela i postupci njihove upotrebe
JP2016519137A5 (ja)
JP2018510132A5 (ja)
JP2011528896A5 (ja)
IL278014B2 (en) Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use
ES2662529T3 (es) Procedimiento para mejorar la eliminación de virus en la purificación de proteínas
RU2018113505A (ru) Il-8-связывающие антитела и их применения
JP2011525523A5 (ja)
JP2010502207A5 (ja)
JP2013537416A5 (ja)
JP2016526885A5 (ja)
JP2013236633A5 (ja)
JP2014523238A5 (ja)
IL288541B (en) vaccine against rsv
BR0211807A (pt) Derivados ativos amino-ftalazinona como inibidores de cinase, processo para sua preparação e composições farmacêuticas para os mesmos
JP2014520142A5 (ja)
JP2016501829A5 (ja)
JP2017529870A5 (ja)
JP2018511325A5 (ja)
RU2015122666A (ru) Полипептиды для переноса через гематоэнцефалический барьер
JP2015509506A5 (ja)